Trenbolone undecanoate, or trenbolone undecylate, is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed.[1][2] It is the C17β undecanoate (undecylate) ester and a long-acting prodrug of trenbolone.[1][2] The drug was described by Roussel Uclaf in 1967 and was the first long-lasting ester of trenbolone to be developed.[1][2] Subsequently, trenbolone hexahydrobenzylcarbonate, a roughly equivalent compound, was developed and introduced for use in humans in 1980, though it was discontinued in 1997.[2] Trenbolone enanthate is another long-lasting ester of trenbolone.[2] Similarly to trenbolone undecanoate, it was never marketed, but it has been sold on the black market as a designer steroid for bodybuilders and athletes.[2]
Clinical data | |
---|---|
Other names | Trenbolone undecylate; Estra-4,9,11-trien-17β-ol-3-one 17β-undecylate |
Routes of administration | Intramuscular injection |
Drug class | Androgen; Anabolic steroid; Androgen ester; Progestogen |
Identifiers | |
| |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H41O3 |
Molar mass | 437.644 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ a b c Mathieu, J (1967). Proceedings of the International Symposium on Drug Research, Montreal, Canada, June 12-14, 1967. Chemical Institute of Canada, Medical Chemistry Group, Montreal, Canada. p. 134.
- ^ a b c d e f William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. p. 619. ISBN 978-0-9828280-1-4.
Further reading
edit- Yarrow JF, McCoy SC, Borst SE (2010). "Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity". Steroids. 75 (6): 377–89. doi:10.1016/j.steroids.2010.01.019. PMID 20138077. S2CID 205253265.